Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial

scientific article published on 16 July 2016

Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1027095739
P356DOI10.1186/S13063-016-1442-X
P932PMC publication ID4947254
P698PubMed publication ID27422026

P50authorPaul DarkQ42039600
Daniel F McAuleyQ60731761
Gavin D PerkinsQ73199096
John SimpsonQ73365495
P2093author name stringBronagh Blackwood
Ronan McMullan
Savita Gossain
Niall H Anderson
Suveer Singh
Andrew Conway Morris
Thomas P Hellyer
Tim S Walsh
Ashley M Agus
Jennie Parker
Lydia M Emerson
Tina Van Den Broeck
P2860cites workGuidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaQ22241905
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trialsQ24614759
Ventilator-associated pneumoniaQ28212947
Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumoniaQ33838052
Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumonia.Q34442582
A national survey of the diagnosis and management of suspected ventilator-associated pneumonia.Q34767855
The standardization of bronchoscopic techniques for ventilator-associated pneumoniaQ35484329
Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsiesQ35532816
Accuracy of clinical definitions of ventilator-associated pneumonia: comparison with autopsy findings.Q40384857
Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsyQ40704822
Antibiotic use in 530 French hospitals: results from a surveillance network at hospital and ward levels in 2007.Q43004333
Safety and tolerability of nonbronchoscopic lavage in ARDS.Q47817247
Ventilator-associated pneumonia is characterized by excessive release of neutrophil proteases in the lungQ84842383
P2507corrigendum / erratumErratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'.Q42390919
P433issue1
P921main subjectpneumoniaQ12192
ventilatorQ813243
biomarkerQ864574
study protocolQ111908491
P304page(s)318
P577publication date2016-07-16
P1433published inTrialsQ7840023
P1476titleEffectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial
P478volume17

Reverse relations

cites work (P2860)
Q91765577Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation
Q64251066Biomarkers in Pneumonia-Beyond Procalcitonin
Q42390919Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'.
Q94562624Intensive Care Society State of the Art 2018 Abstracts
Q64054907Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia

Q42390919Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'.main subjectP921

Search more.